<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756145</url>
  </required_header>
  <id_info>
    <org_study_id>2008/421</org_study_id>
    <nct_id>NCT00756145</nct_id>
  </id_info>
  <brief_title>The Use of Low Molecular Weight Heparin in Hemodiafiltration</brief_title>
  <official_title>The Use of Low Molecular Weight Heparin in Hemodiafiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the
      session. In the present study we compare 3 different methods of injection of LMWH: parameters
      of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each
      patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Xa activity at the end of the session</measure>
    <time_frame>240 min after start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Xa activity during the session</measure>
    <time_frame>at start, 30 min, 120 min and 180 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETP during the session</measure>
    <time_frame>at start, 30 min, 120 min, 180 min and 240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction ratio of urea</measure>
    <time_frame>after 10min, 180min and 240min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction ratio of beta2microglobulin</measure>
    <time_frame>after 10min, 180min and 240min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual inspection of membrane and circuit</measure>
    <time_frame>After the hemodiafiltration session</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pressure measurements along the circuit</measure>
    <time_frame>during the session</time_frame>
    <description>inlet blood line, prefilter, transmembrane, outlet blood line</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>At start of the session, at the inlet line</intervention_name>
    <description>Injection of LMWH at the inlet line, at the start of the hemodiafiltration session</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>5 minutes after the start of the session, at the inlet line</intervention_name>
    <description>Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>At the start of the session, at the outlet line</intervention_name>
    <description>Injection of LMWH at the outlet line, at the start of the hemodiafiltration session</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic kidney disease stade V treated with hemodiafiltration

          -  age &gt;18 year

          -  Hematocrit &gt; 30%

        Exclusion Criteria:

          -  treatment with vitamin K antagonists

          -  treatment with other anti-coagulants or heparin besides the heparin used during
             dialysis

          -  active bleeding, infection or malignancy

          -  heparin associated allergy

          -  hepatic failure

          -  trombocytopenia &lt; 120.000/Âµl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annemieke Dhondt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage V</keyword>
  <keyword>treated</keyword>
  <keyword>hemodiafiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

